Gloria Kayani

Thrombosis Research Institute — United Kingdom

Medicine · Health Sciences

29h-index2.7kcitations89works3.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Atrial Fibrillation Management and Outcomes(74), Venous Thromboembolism Diagnosis and Management(47), Cardiac Arrhythmias and Treatments(27), Health Systems, Economic Evaluations, Quality of Life(14), Acute Ischemic Stroke Management(10)

Publications89 total

Incidence and risk factors of post-thrombotic syndrome in patients with isolated calf vein thrombosis. Findings from the GARFIELD-VTE registry
Thrombosis Research·2024· 3 cited
Comparing U.S. and Canadian treatment patterns on venous thromboembolism outcomes in the GARFIELD-VTE registry
Thrombosis Research·2023· 1 cited
Incidence and predictors of post-thrombotic syndrome in patients with proximal DVT in a real-world setting: findings from the GARFIELD-VTE registry
Journal of Thrombosis and Thrombolysis·2023· 10 citedOpen Access
Patients with AF and dementia are undertreated for their AF and cardiovascular comorbidities: results from the GARFIELD-AF registry
European Heart Journal·2023Open Access
Clinical Outcomes in Older Patients with Atrial Fibrillation: Insights from the GARFIELD-AF Registry
The American Journal of Medicine·2023· 6 citedOpen Access
PB0049 Thromboprophylaxis with Enoxaparin for Symptomatic COVID-19 Managed in the Ambulatory Setting: Pooled Analysis of the OVID and ETHIC Trials
Research and Practice in Thrombosis and Haemostasis·2023Open Access
Outcomes of Oral Anticoagulation in Atrial Fibrillation Patients With or Without Comorbid Vascular Disease: Insights From the GARFIELD-AF Registry
The American Journal of Medicine·2023· 3 citedOpen Access
Enoxaparin for symptomatic COVID-19 managed in the ambulatory setting: An individual patient level analysis of the OVID and ETHIC trials
Thrombosis Research·2023· 4 citedOpen Access
Oral anticoagulation across diabetic subtypes in patients with newly diagnosed atrial fibrillation: A report from the <scp>GARFIELD‐AF</scp> registry
Diabetes Obesity and Metabolism·2023· 4 citedOpen Access
Author response for "Oral anticoagulation across diabetic subtypes in patients with newly diagnosed atrial fibrillation: A report from the &lt;scp&gt;GARFIELD‐AF&lt;/scp&gt; registry"
2023
CO8 Design and Rationale of a Global Prospective Observational Study of Real-World Management of Patients with Atrial Fibrillation at High Risk of Stroke- Gardenia
Value in Health·2023Open Access
Determinants and clinical outcomes of patients who refused anticoagulation: findings from the global GARFIELD-AF registry
Open Heart·2023· 4 citedOpen Access
Author response for "Oral anticoagulation across diabetic subtypes in patients with newly diagnosed atrial fibrillation: A report from the &lt;scp&gt;GARFIELD‐AF&lt;/scp&gt; registry"
2023
Healthcare Resource Utilization in Patients with Newly Diagnosed Atrial Fibrillation: A Global Analysis from the GARFIELD-AF Registry
Healthcare·2023· 4 citedOpen Access
36-month clinical outcomes of patients with venous thromboembolism: GARFIELD-VTE
Thrombosis Research·2022· 26 citedOpen Access
Differential efficacy and safety of oral anticoagulation in atrial fibrillation patients with or without comorbid vascular disease: insights from the GARFIELD-AF registry
European Heart Journal·2022Open Access
On-treatment Comparative Effectiveness of Vitamin K Antagonists and Direct Oral Anticoagulants in GARFIELD-VTE, and Focus on Cancer and Renal Disease
TH Open·2022· 9 citedOpen Access
GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide
Clinical Research in Cardiology·2022· 12 citedOpen Access
Association of body mass index with outcomes in patients with newly diagnosed atrial fibrillation: GARFIELD-AF
Open Heart·2022· 4 citedOpen Access
Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial
The Lancet Haematology·2022· 60 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

Ajay K. Kakkar(50), Sylvia Haas(45), Samuel Z. Goldhaber(40), Shinya Goto(40), LG Mantovani(30), Karen S. Pieper(28), Jean‐Pierre Bassand(25), A. John Camm(25), Pantep Angchaisuksiri(25), David Fitzmaurice(21), Frank Misselwitz(21), Sebastian Schellong(21), Walter Ageno(20), Alexander G.G. Turpie(19), Keith A.A. Fox(17), Jeffrey I. Weitz(17), Henri Bounameaux(17), Martin van Eickels(15), Paolo Prandoni(15), Frank Cools(14)